Table 2.
PLP TCR-transgenic mice are very sensitive to induction of EAE
| Mice | Incidence of Clinical Disease | Mean Day of Onset | Mean Peak Disease Severity |
|---|---|---|---|
| PLP/CFA | |||
| TG | 7/7 | 11.9 ± 7.3∗ | 2.6 ± 0.9† |
| NLM | 4/5 | 27.0 ± 6.6 | 1.4 ± 0.5 |
| PT | |||
| TG | 5/6 | 10.6 ± 6.5 | 2.1 ± 0.7 |
| NLM | 0/6 | N/A | N/A |
| PLP/CFA/PT | |||
| TG | 7/7 | 7.2 ± 0.8‡ | 3.7 ± 1.0§ |
| NLM | 6/6 | 14.5 ± 3.2 | 2.3 ± 0.4 |
5B6 TCR transgenic (TG) and nontransgenic littermate (NLM) mice were injected with PLP-139–151 in CFA (PLP/CFA) s.c. or PT i.v. alone or in combination (PLP/CFA/PT). EAE was monitored for 40 days. Mean day of onset and mean peak disease severity are shown with SD. ∗, P = 0.008 versus NLM; †, P = 0.04 versus NLM; ‡, P = 0.0001 versus NLM; §, P = 0.008 versus NLM (all Student's t test, unpaired).